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STUDY PROTOCOL Open Access
The immune response to 6-monthly versus
annual standard dose inactivated trivalent
influenza vaccination in older people: study
protocol for a randomised clinical trial
Barnaby Young1,2* , Sapna Sadarangani1,2, Haur Sen Yew1, Chee Fu Yung3, Yee Sin Leo1,2,4,
Mark I-Cheng Chen1,4 and Annelies Wilder-Smith1,2
Abstract
Background: The seasonal influenza vaccine is less effective in older people and a single dose is unlikely to provide
the year-round protection necessary for tropical climates which have year-round influenza virus activity. This study
aims to assess the effect of a trivalent inactivated influenza vaccine (IIV3) booster at 180 days on
haemagglutination-inhibition (HI) antibody titres for each of the influenza strains present in the administered
vaccine in older people aged 65 years or above in Singapore.
Methods/design: This is a single-centre, randomised, observer-blind, active-comparator controlled, parallel-group,
phase IV trial in 200 adults aged 65 years or older. Study participants will be assigned to one of two groups in a 1:1
ratio and followed for 1 year, with five scheduled visits. The control group will receive IIV3 at day 1, and an active
comparator (Tetanus-diphtheria-pertussis vaccine) at day 180. Participants in the experimental group will receive
IIV3 containing the same strains at day 1 and day 180. Endpoints are immunological, and include measures of HI
titres, microneutralisation titres (MN) and cell-mediated immunity from first vaccination up to day 360.
Discussion: If superiority of 6-monthly influenza vaccination is demonstrated, this study could form the basis for a
larger clinical trial with influenza infection as the primary endpoint.
Trial registration: ClinicalTrials.gov, ID: NCT02655874. Registered on 12 January 2016.
Keywords: Influenza, Vaccine, Antibody persistence, Tropics, Haemagglutination inhibition, Older people
Background
Influenza is popularly characterised as an infection ac-
quired during the cold, winter months in temperate cli-
mates. Tropical and subtropical countries also have a
significant burden of disease from influenza but the epi-
demiology is much more variable [1, 2]. This includes
multiple annual influenza seasons and year-round virus
activity [3, 4]. The implications of this for influenza vac-
cination schedules have not been tested in randomised
clinical trials but are likely to be important in older
people and in other populations with impaired vaccine
responses.
Year-round influenza virus activity implies that an ef-
fective vaccine must also provide year-round protection.
However, the duration of protection provided by the in-
fluenza vaccine has not been well established. No clinical
studies of vaccine efficacy or effectiveness are available
from countries with year-round influenza activity, but
over the course of a single winter season declining vac-
cine effectiveness has been reported from test-negative
case control studies in Europe and Australia [5–7]. For
example, in Spain vaccine effectiveness was 61% (95% CI
5 to 84) in the first 100 days after vaccination, 42% (95%
CI −39 to 75) between 100 and 119 days, and 0%
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thereafter. This decline in effectiveness mainly affected
older people aged over 65 years [6].
In response to these reports, the I-MOVE multicentre,
test-negative, case-control study reviewed data collected
from more than 11,000 seasonal influenza infections
over 2010–2015 in eight European countries [8]. Vaccine
effectiveness against influenza A/H3N2 and B infection
declined across all age groups as the winter season pro-
gressed. This decline was most marked in older people,
with little vaccine effectiveness evident by day 140 (sub-
type A/H3N2) or day 200 (influenza B). Surprisingly,
vaccine effectiveness appeared to be maintained (over
200 days) for subtype A/H1N1. The authors hypothesise
that this may reflect the homogeneity of the A/H1N1
strain (pdm2009) across the period of the study, with
repeated vaccination (or infections) boosting strain-
specific antibody titres.
As an alternative to clinical effectiveness, the trajectory
of immune responses after vaccination can be used to
estimate the duration of protection. The haemagglutination
inhibition (HI) titre is the major immune correlate of pro-
tection, and is used by regulatory agencies, such as the
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA), for influenza vaccine licensing.
A titre ≥1:40 is estimated to offer 50% protection against
infection, and this threshold is conventionally labelled as
‘seroprotection’ [9]. A systematic review of vaccine anti-
body persistence studies, performed by the study team in
preparation for this trial, suggested that in older people
there is a steady decline in HI titres, and at between 180
and 360 days titres return to the pre-vaccination level [10].
Studies have identified increasing age and lower pre-
existing HI titres as predicting reduced duration of anti-
body persistence, while the impact of comorbidities, such
as diabetes, on persistence is less clear [11, 12].
Primary objective
The study aims to assess the effect of a trivalent inactivated
influenza vaccine (IIV3) booster at 180 days on HI anti-
body titres for each of the influenza strains present in the
administered vaccine in adults, aged 65 years and older.
Secondary objectives
 To compare the antibody response (HI and
microneutralisation (MN) titres) at 360 days after
IIV3 and IIV3 + booster
 To compare the immune response between primary
and booster IIV3 vaccination
 To assess the safety of an IIV3 booster at 180 days
We hypothesise a booster injection of seasonal IIV3 at
180 days after primary vaccination improves year-round
seroprotection against influenza infection in older
people aged 65 years and above.
Methods/design
Summary of study design
This is a single-centre, randomised, observer-blind,
active-comparator controlled, parallel-group, phase IV
trial in 200 adults aged 65 years or older. Each study
participant who meets eligibility criteria and signs the
Informed Consent Form will be allocated to one of two
groups in a 1:1 ratio (Fig. 1). Participants will be followed
for 1 year, with five scheduled visits. All participants
will provide blood samples for immunogenicity assess-
ment at days 1 (pre-injection), 28, 180 (pre-injection),
208, and 360 (Fig. 2).
Solicited and unsolicited adverse events (AEs) will be
collected for all participants for 7 days after each vaccin-
ation. All serious adverse events (SAEs) will be collected
for 28 days after each vaccination. SAEs that are consid-
ered related to vaccination and/or study procedures will
be monitored until resolution or stable. Participants will
also be contacted 2-weekly as surveillance for clinical
endpoints, including influenza-like illnesses (ILI) and
polymerase chain reaction (PCR)-confirmed influenza.
Randomisation
A web-based, computer-generated randomisation code will
assign participants using a random permuted block
method. Allocation will be stratified by age (65 years or
under to 74 years, 75 years or older). Age is a significant
predictor of response to vaccination, and the propor-
tion of participants recruited who are older than 75
years may be small.
Blinding
To minimise the potential for unintentional bias an
observer-blind procedure will be followed. The partici-
pant, investigators, study staff members, and laboratory
personnel will all be blinded to group assignment. One
or more unblinded vaccine administrators will perform
randomisation and will be responsible for both preparing
and administering the blinded vaccine. This person will
not be authorised to collect any safety data or to per-
form any other study procedures. This person will not
provide any information about the contents of the
Fig. 1 Stratified randomisation by age at enrolment day 1
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syringe to study participants or personnel, and will not
allow anyone to see the content of the syringe. Blinded
study personnel will not be present during product prep-
aration and administration. The vaccine will be adminis-
tered in a private setting with no observers present.
Contents of the syringe will be masked with an opaque
tape to ensure participant blinding to group allocation.
The unblinded staff will ensure that vaccination docu-
ments revealing participant group assignment are stored
in a secure place to which only they have access.
Unblinding procedures
The vaccine blind will be broken by the investigator in
the event of an SAE if identification of the vaccine re-
ceived could influence treatment of the SAE, or in the
event of death or a life-threatening SAE where the investi-
gator’s causality assessment is ‘related’ to the trial product.
Vaccine blind will also be broken at the request of the
health authority in the event of an SAE. Code-breaking
will be limited, when possible, to the participant(s)
experiencing the SAE. Any intentional or uninten-
tional code breaking will be reported to the Domain
Specific Review Boards (DSRB).
Potential risks
As with any vaccination, participants may experience pain,
swelling, redness or itching at the injection site. Rarely, a
participant may experience an allergic reaction which pro-
duces rash, urticaria or difficulty breathing. Serious allergic
reactions that can be life-threatening may occur. The inci-
dence of severe adverse reactions are low with the trial vac-
cines. An increased risk of SAEs has not been reported
from studies of repeated vaccination at 1 year or earlier.
The risk of nonsevere local and systemic adverse reactions
may be increased with repeated vaccination as a result of
increased reactogenicity from pre-existing immunity. Blood
taking is a common medical procedure with very low risk
of complications, such as prolonged bleeding or infection,
when standard procedures are followed. Risks of breaches
in trial participant confidentiality will be ameliorated by
following the Singapore Guideline for Good Clinical Prac-
tice (SGGCP) and the DSRB-approved study protocol.
Potential benefits
There is a possibility that the booster vaccine adminis-
tered in the experimental arm will prevent an influenza
infection that might otherwise have occurred. There is
also a possibility that the vaccine administered in the
control arm will prevent a tetanus, diphtheria or pertus-
sis episode that might otherwise have occurred. Partici-
pants will not be paid for participation in this study, but
will be reimbursed for their time and travel costs.
Study population
Two hundred participants will be enrolled (approxi-
mately 100 per group). The study population will be
drawn from people attending outpatient services at Tan
Tock Seng Hospital, Singapore and healthy volunteers
from senior activity centres and community clubs in
Singapore. There are no participant restrictions based on
sex or race. A complete review of the inclusion and exclu-
sion criteria for eligibility will be performed. This will en-
tail a face-to-face interview with the potential participant
and screening of electronic medical records. The potential
participant will be provided with information about the
trial and written informed consent obtained. No proced-
ure or treatment associated with the study will be per-
formed before obtaining written informed consent.
Inclusion criteria
Participants must meet all of the inclusion criteria to
participate in this study:
 Age 65 years or older on the day of inclusion
 No influenza vaccination in the previous 10 months
 No tetanus, diphtheria or pertussis vaccine in the
previous 1 year
 No virologically confirmed influenza infection in the
previous 10 months
 Participant able to provide written informed consent
 Able to attend all scheduled visits and comply with
all trial procedures
Exclusion criteria
Participants meeting any of the exclusion criteria at
baseline will be excluded from participation:
 Participation in the 4 weeks preceding the first trial
vaccination or participation during the present trial
period in another trial investigating a vaccine, drug,
medical device, or medical procedure
 History of a life-threatening reaction to the vaccine
used in the trial, or to a vaccine containing any of
the same substances
 Known systemic hypersensitivity to any of the
vaccine components, including:
 Egg protein (eggs or egg products)
 Chicken products
 Formaldehyde
 Neomycin or kanamycin
 Octoxinol 9 (Triton X-100)
Fig. 2 Study timeline from day 1 (D1) to day 360 (D360)
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 Cetyltrimethylammonium bromide (CTAB)
 Thiomersal
 History of Guillain-Barré syndrome (GBS) within 6
weeks following previous influenza vaccination
 Acute respiratory infection (ARI) on the day of
enrolment
 Moderate or severe acute illness/infection
(according to investigator judgement) on the day of
vaccination, or febrile illness (temperature ≥37.5 °C).
A prospective participant should not be included in
the study until the condition has resolved or the
febrile event has subsided
 Self-reported thrombocytopenia, contraindicating
intramuscular (IM) vaccination
 Known or suspected congenital or acquired
immunodeficiency; or receipt of immunosuppressive
therapy, such as anticancer chemotherapy or radiation
therapy, within the preceding 6 months; or long-term
systemic corticosteroid therapy (prednisolone ≥7.5
mg/day or equivalent for more than two consecutive
weeks within the past 3 months)
 Chronic illness that, in the opinion of the
investigator, is at a stage where it might interfere
with trial conduct or completion
 Deprivation of freedom by an administrative or
court order, or in an emergency setting, or
hospitalised involuntarily
 Current alcohol abuse or drug addiction that might
interfere with the ability to comply with trial
procedures in the opinion of the investigator
 Women of childbearing age will be excluded from
the trial
Participant withdrawal
Participants will be informed that they have the right to
withdraw from the trial at any time. Participants who
are withdrawn will not be replaced. If withdrawal occurs
within 28 days after vaccination, and if agreeable, the
participant will continue to be contacted by telephone at
expected visits to confirm AE or SAE status.
The investigator will discontinue vaccination if the
participant experiences any SAE related to the administra-
tion of the previous vaccine, including an anaphylactic or
other significant allergic reaction. In addition, a partici-
pant may be withdrawn from the study if, in the investiga-
tor’s judgement, there are safety concerns, or significant
noncompliance with the study protocol. If a participant
experiences an AE or SAE considered by the investigator
to be related to vaccination, the participant will be
followed until the condition resolves or becomes stable.
Primary outcome
The primary outcome is the percentage of participants
with seroprotection (HI titre ≥1:40) at day 208 post
primary vaccination for each of the influenza strains
present in the administered influenza vaccine.
Secondary outcomes
The secondary outcomes are as follows:
 Comparison by vaccination group of Geometric Mean
Titres (GMTs) against homologous and heterologous
influenza strains from day 208 to day 360
 Comparison by vaccination group of the Geometric
Mean Ratio (GMR) of HI titres post versus pre-
vaccination (day 1), against homologous and
heterologous strains from day 208 to day 360
 Comparison by vaccination group of seroprotection
rates (HI titre ≥1:40) against homologous and
heterologous strains from day 208 to day 360
 Comparison by vaccination group of participants
with seroconversion against homologous and
heterologous strains from day 208 to day 360
(seroconversion is defined as a pre-vaccination (day 1)
HI titre <10 and post-vaccination HI titre ≥40 or
at least a four-fold increase in HI titres from a
pre-vaccination HI titre ≥10)
 Comparison by vaccination group of MN titres
against homologous and heterologous strains from
day 208 to day 360
 Number of participants reporting ILI across vaccine
groups from day 208 to day 360
 Number of participants with PCR-confirmed
influenza across vaccine groups from day 208
to day 360
 Number of participants reporting healthcare
utilisation (emergency room visits, unscheduled
physician visits, and hospitalisations in each group)
across vaccine groups from day 180 to day 360
 All-cause mortality rate, across vaccine groups from
day 180 to day 360
 Frequency and severity of solicited local (injection
site) and systemic AEs for 7 days post vaccination.
The frequency of the following AEs will be reported
per regulatory guidance (CPMP/BWP214/96):
indurations larger than 50 mm in diameter and
persisting for more than 3 days, ecchymosis,
temperature >38 °C for 24 h or more, malaise,
shivering
 Percentage of participants with SAE from day 1 to
day 360
Study schedule, visits and procedures
The study schedule is presented in Fig. 3.
Blood sample analysis
HI and MN antibody testing will be performed by col-
laborators at a central laboratory. Antibody assays will
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be performed using standard methods recommended by
the World Health Organisation (WHO) [13]. As both as-
says are subject to considerable interlaboratory variabil-
ity, assays will be conducted at a single, experienced
laboratory using the same technique.
Influenza surveillance
For all participants, there will be 2-weekly contact (tele-
phone, home visit, or clinic visit) from enrolment to day
360. The method of contact can vary (e.g. telephone, text
message, or email); however, there should be participant
contact via telephone or face-to-face visit once a month.
At each contact, participants will be asked regarding any
symptoms meeting protocol definition of an acute re-
spiratory illness, any unscheduled physician visits (e.g.
general practitioner, polyclinic, emergency department)
or hospitalisations since the previous contact. Partici-
pants will also be instructed to contact the study team if
they develop any acute respiratory symptoms.
Study investigators will determine whether symptoms
meet the European Centre for Disease Prevention and
Control (ECDC) definition of an ARI:
1. Sudden onset of symptoms
2. And at least one of the following four systemic
symptoms:
 Fever or feverishness
 Malaise
 Headache
 Myalgia
3. And at least one of the following respiratory
symptoms:
 Cough
 Sore throat
 Shortness of breath
 Coryza
If symptoms meet the criteria for an ARI, a study team
member will visit the participant to collect a nasopha-
ryngeal swab within 5 days after onset of the illness.
Influenza and other respiratory viral pathogens in naso-
pharyngeal swabs will be detected using a PCR assay. No
additional blood samples will be collected during ARI
episodes.
Trial materials
All trial products will be dosed according to Singapore
licenses. The vaccine formulation containing the most
recent WHO recommendations for strain identity at the
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) flow diagram of study enrolment, interventions
and assessments
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start of the trial will be used. Southern Hemisphere winter
2016 and Northern Hemisphere winter 2016/7 recom-
mendations are as below, but may change during the trial:
 A/California/7/2009 (H1N1)pdm09-like virus
 A/Hong Kong/4801/2014 (H3N2)-like virus
 B/Brisbane/60/2008-like virus
Participants will receive one injection of 0.5 ml standard
dose, inactivated IIV3 at days 1, and no or one injection at
day 180 depending on group allocation. Participants
will receive no or one injection of 0.5 ml Tetanus-
diphtheria-pertussis vaccine (TDap) at 180 days de-
pending on group allocation.
Treatment compliance and specific restrictions
The following measures will ensure that the vaccine
doses administered comply with those planned, and that
any noncompliance is documented so that it can be
accounted for in the data analyses. All vaccines will be
administered by qualified trial personnel, the person in
charge of product management will maintain account-
ability records of product delivery to the trial site, product
inventory at the site, doses given to each participant, and
the disposal of unused or wasted doses. Participants will
be asked not to take any influenza vaccinations except as
provided by the study team for the duration of the study.
This restriction will not apply in the event of a national
immunisation programme by the Ministry of Health for a
pandemic influenza vaccine. There are no restrictions on
other vaccines. If prescribed at the same visit they will be
administered to a separate body site. There are no limita-
tions on medications, herbs, vitamins, and mineral supple-
ments while participating in the study.
Safety measurements
AEs, SAEs and ‘Unanticipated Problems Involving Risk
to Participants or Others’ (UPIRTSO) events are defined
below. Events will be reviewed and graded by the princi-
pal investigator (PI) or other investigator. Only members
of the study team blinded to participant group allocation
will be involved in safety assessment. Severity will be
classified using the Common Terminology for Adverse
Events version 4.03. The relationship of the event to the
study drug, and whether the event is an expected event
or not, will be assessed using the list of AEs contained in
the product summary of characteristics.
Adverse event (AE)
An AE is any untoward medical occurrence in a partici-
pant administered a trial product. It does not necessarily
have a causal relationship with this product. Pre-existing
medical conditions are not reported as an AE; an AE
may be a new illness, the worsening of a concomitant
illness or an effect of vaccination. All AEs include ser-
ious and nonserious AEs. Surgical procedures are not
AEs; they are the action taken to treat a medical condi-
tion. The condition leading to the surgical procedure is
the AE, if it occurs during the trial period. AEs will be
further categorised as solicited and unsolicited AEs.
A solicited AE is a reaction that is prelisted in the
electronic Case Report Form (eCRF). It is defined by na-
ture and time of onset post vaccination, and is consid-
ered to be related to vaccination. Unsolicited AEs are all
observed AEs which do not fulfil the conditions for a
solicited AE, as described above.
Serious adverse events (SAEs)
A SAE is defined as any untoward medical occurrence
that: results in death, is life-threatening (immediate risk
of death), requires inpatient hospitalisation or prolonga-
tion of existing hospitalisation, results in persistent or
significant disability/incapacity, results in congenital
anomaly/birth defect, or is a medically important event.
Medical and scientific judgment will be exercised in de-
termining whether an event is an important medical
event. An important medical event may not be immedi-
ately life-threatening and/or result in death or hospital-
isation. However, if it is determined that the event may
jeopardise the participant and/or may require interven-
tion to prevent one of the other AE outcomes, the im-
portant medical event should be reported as serious.
Collecting, recording and reporting of SAEs to the Health
Sciences Authority (HSA)
All SAEs that are unexpected and related to the study
drug will be reported to the HSA within 15 calendar
days after initial notification to the PI. For fatal or life-
threatening cases, the HSA will be notified as soon as
possible, but no later than seven calendar days after first
knowledge that a case qualifies. A complete report will
then follow within eight additional calendar days.
Collecting, recording and reporting of UPIRTSO events to
the National Healthcare Group Domain Specific Review
Boards (NHG DSRB)
Any events that are unexpected (in terms of severity or
frequency), that can be reasonably attributed to the study
drug and that may expose other participants to harm will
be reported. A UPIRTSO event refers to problems, in
general, that include any incident, experience, or outcome
(including AEs) which meet all of the following criteria:
1. Unexpected, in terms of nature, severity, or frequency of
the problem as described in the study documentation
(e.g. protocol, consent documents, etc.)
2. Related or possibly related to participation in the
research. Possibly related means that there is a
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reasonable possibility that the problem may have been
caused by the procedures involved in the research, and
3. Risk of harm. This suggests that the research places
participants or others at a greater risk of harm
(including physical, psychological, economic, or social
harm) than was previously known or recognised
For urgent reporting, all problems involving local
deaths, whether related or not, should be reported imme-
diately – within 24 h after first knowledge by the investi-
gator. For expedited reporting, all other problems must be
reported as soon as possible but not later than seven cal-
endar days after first becoming known to the investigator.
Safety assessment methods
To ensure participants’ safety, there will be an immediate
post-vaccination surveillance period. Participants will be
kept under observation for 15 min after each vaccination.
AEs will not be actively solicited during this surveillance
period. To collect solicited AEs, all participants will be
provided with a safety diary card, a digital thermometer,
and a flexible ruler and will be instructed how to use
them. The following items will be recorded in the diary
card on the day of vaccination and for the next 6 days or
until resolution: daily temperature with the route by which
it was taken; daily measurement or intensity grade of all
other solicited injection site and systemic reactions; action
taken for each event (e.g. medication), if any. To collect
unsolicited AEs, all participants will be instructed to rec-
ord any unsolicited AEs that may occur for 7 days after
each vaccination. Space will be provided in the diary card
for this purpose. AEs which are likely to be related to trial
products, whether serious or not, will be followed up by
the investigator until their complete disappearance or sta-
bilisation. Information on all SAEs and UPIRTSO events
will be collected and assessed throughout the trial, from
enrolment until the final study visit (day 360).
Safety monitoring plan
All vaccines used in this study are part of routine vaccin-
ation schedules. Safety data has been established from
millions of administered doses. According to the WHO,
the incidence of vaccine-related SAEs, such as anaphyl-
axis and GBS, is approximately 1 per million doses. The
rate of mild, nonsevere AEs in clinical trials is similar
between influenza vaccine and placebo. Vaccine-related
SAEs are not expected in a clinical trial of this size. AEs
will be monitored for the first 7 days after each vaccin-
ation. SAEs will be monitored for the first 28 days after
each vaccination. An interim safety analysis will not be
performed. The study team will review any UPIRTSO
events and stop the trial if significant risk to participants
from continuing in the trial is suspected.
Data entry and storage
Paper Case Report Forms (CRFs) will be used for initial
data collection. These will be transcribed to an eCRF de-
veloped with an independent web-based hosting facility
called Research Electronic Data Capture (REDCap). The
trial database will include information on demographics
(age, gender), underlying illnesses, concomitant medica-
tions and vaccination history. AE and SAE data will also
be entered. Paper documents will be maintained and
stored in a locked office, with access restricted to study
personnel. All electronic documents with participant in-
formation will be password-protected.
Data quality assurance
A random sample of source documents and CRFs will
be audited to substantiate the integrity of trial data en-
tered into the electronic database.
Sample size calculation
The following assumptions were made for determination
of sample size expected to meet primary outcome:
1. Rate of seroprotection (HI antibody titre ≥1:40) on
day 208 after vaccination is 60%
2. Proportion seroprotected at day 208 in the
experimental group will be 80%
3. A loss to follow-up rate of 10%
4. A power (1 − β) of 80% to detect differences between
the two primary study groups
5. A two-sided significance level (α) of 5%
The primary statistical null hypothesis is of no increase
in seroprotection rates (HI antibody titre ≥1:40) at day
208 following booster IIV3 vaccination, compared to a
control injection. Formally, the trial will test:
H0: Seroprotection rate (booster) = seroprotection rate
(control), versus
HA: Seroprotection rate (booster) ≠ seroprotection rate
(control)
A sample size of 164 (82 per group) will provide 80%
power to test this hypothesis, based on approximations
to the normal distribution. A total sample size of 200
(100 per group) has been chosen to allow for up to 15%
dropout. This sample size will provide adequate power
for a range of seroprotection rates assuming an increase
in absolute seroprotection of at least 20%.
Statistical analysis
The full analysis set (FAS) consists of all participants who
received at least one injection. Participants will be analysed
according to the group to which they were randomised.
The per-protocol analysis set (PPS) is a subset of the FAS
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who have no major protocol violations. Participants pre-
senting with at least one of the following protocol devia-
tions will be excluded from the per protocol analysis:
participant did not meet all protocol-specified inclusion cri-
teria or met at least one of the protocol-specified exclusion
criteria; participant did not complete the vaccination sched-
ule; participant received a different vaccine than the one
randomised to receive; participant did not receive vaccine
within the protocol-determined time window; participant
received additional seasonal trivalent influenza vaccines
during the trial period; preparation and/or administration
of the vaccine was not performed as per protocol.
The safety analysis set is defined as those participants
who have received at least one vaccine. All participants
will have their safety analysed according to the vaccine
that they actually received. The FAS will be the primary
analysis to infer superiority of a 180-day IIV3 booster
vaccination compared to the active-comparator control
in terms of the proportion of participants with day-208
HI antibody titres ≥1:40. This will be supported by per-
protocol analysis. Analysis of secondary endpoints will
use both the FAS and PPS.
Immunological data will be analysed per CHMP guid-
ance (EMA/CHMP/VWP/457259/2014). Results will be
presented by vaccine strain and will include GMTs (with
95% confidence intervals) and pre-/post-vaccination ra-
tios (GMRs). Reverse cumulative distribution curves will
also be provided, supplemented by tables presenting per-
centages of vaccinees with titres above a range of cut-off
levels on a logarithmic scale.
Confidentiality and retention of trial documents
All study findings and documents will be regarded as
confidential. The investigators and other study personnel
will not disclose such information without prior written
approval from the PI. Participant confidentiality will be
strictly maintained to the extent possible under the law
and as required by the SGGCP. Identifiable information
will be removed from any published data. Any electronic
data records stored locally will be kept on a networked,
password-protected, single computer within the Depart-
ment of Infectious Diseases. The PI will keep any paper-
based records, DSRB files or source documentation in a
locked cabinet within the department. These records,
electronic and physical, will be kept for a minimum of 6
years after trial completion, before being destroyed or
erased as per SGGCP requirements.
SPIRIT Checklist
Please see Additional file 1 for the SPIRIT Checklist
Discussion
This clinical trial addresses a neglected issue in tropical
countries. Demonstrating superior protection against
influenza infection with a simple booster vaccination has
the potential to offer a significant public health benefit.
For example, in South East Asia alone, demographic esti-
mates by the United Nations are for the number of per-
sons aged 65 years and older to almost triple over the next
30 years, from 37.6 million in 2015, to 111.3 million in
2045 [14].
A 6-monthly booster schedule with standard dose
inactivated trivalent vaccine is attractive due to its sim-
plicity, low cost, and safety profile. This would support
its implementation into clinical practice if proven to
offer superior efficacy against influenza infection. Six-
monthly vaccination coincides with the approximate
periodicity of epidemics in countries with biannual sea-
sons synchronous with the Northern and Southern
Hemisphere winters. A 6-monthly schedule also coin-
cides with WHO strain recommendations which, since
1999, have been made biannually [15]. Between hemi-
sphere winters, a change in at least one of the strains in
the trivalent vaccine has been recommended approxi-
mately half of the time (19/37 from 1999 till the SH
2017 recommendations). Repeat vaccinations are not as-
sociated with an increased risk of AEs, though data is
not available for 6-monthly vaccination [16].
The limitations in older people of standard dose inac-
tivated influenza vaccine are well understood [17]. Even
if this study finds a significant immunological benefit
from repeat vaccination at 6 months, this may not be
the optimal solution for providing year-round protec-
tion. Alternative influenza vaccine formulations have
been licensed for older people; for example, a high-dose
vaccine with 60 μg of haemagglutinin (HA) per strain,
and vaccines which include an immune adjuvant.
These vaccines do offer superior short-term immuno-
genicity in older people, which in some studies per-
sists for at least 6 months [18–20]. However, by 1 year,
either no significant residual benefit is reported (adju-
vanted vaccine), or data is not currently available (high-
dose vaccine) [21, 22].
If evidence of significantly improved seroprotection
by an IIV3 booster can be inferred from this study,
we believe that it will provide the basis for a large-
scale clinical trial in older people to determine
whether this translates into reduced influenza infec-
tion rates.
Trial status
This trial began recruiting participants in May 2016. Re-
cruitment is expected to conclude by the end of 2016,
with the final participant visit by the end of 2017.
Additional file
Additional file 1: SPIRIT Checklist. (DOCX 37 kb)
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